Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
2(22%)
Results Posted
75%(3 trials)
Terminated
2(22%)

Phase Distribution

Ph not_applicable
1
11%
Ph phase_2
4
44%
Ph phase_1
4
44%

Phase Distribution

4

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
4(44.4%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(4)
Terminated(2)
Other(1)

Detailed Status

Completed4
Recruiting2
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (44.4%)
Phase 24 (44.4%)
N/A1 (11.1%)

Trials by Status

completed444%
recruiting222%
terminated222%
unknown111%

Recent Activity

2 active trials
Showing 5 of 9
recruitingphase_1

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

NCT06922591
recruitingphase_1

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

NCT05257993
completedphase_2

Pancreatic Adenocarcinoma Signature Stratification for Treatment

NCT04469556
completedphase_1

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04666688
completedphase_1

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

NCT02009449
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06922591Phase 1

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Recruiting
NCT05257993Phase 1

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Recruiting
NCT04469556Phase 2

Pancreatic Adenocarcinoma Signature Stratification for Treatment

Completed
NCT04666688Phase 1

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Completed
NCT02009449Phase 1

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Completed
NCT02318095Not Applicable

Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer

Completed
NCT01676259Phase 2

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

Unknown
NCT02241551Phase 2

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

Terminated
NCT02243007Phase 2

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Terminated

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9